Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment

Leuk Lymphoma. 2016 Jul;57(7):1723-6. doi: 10.3109/10428194.2015.1113274. Epub 2016 Mar 16.

Authors

Mark-Alexander Schwarzbich¹, Tilman Schöning², Martin Cremer¹, Katharina Lisenko¹, Anthony D Ho¹, Matthias Witzens-Harig¹

Affiliations

¹ a Department of Hematology and Oncology , University Hospital Heidelberg , Heidelberg , Germany ;
² b Department of Pharmacy , University Hospital Heidelberg , Heidelberg , Germany.

PMID: 26980422
DOI: 10.3109/10428194.2015.1113274

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Disease-Free Survival
Febrile Neutropenia / chemically induced
Female
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / pathology
Male
Methotrexate / administration & dosage
Methotrexate / adverse effects
Middle Aged
Mucositis / chemically induced
Retrospective Studies
Risk Factors
Rituximab / administration & dosage
Rituximab / adverse effects
Treatment Outcome
Young Adult

Substances

Rituximab
Methotrexate